Inappropriate 'interchangeability' requirement for biosimilars will cost the U.S. billions - STAT

Inappropriate 'interchangeability' requirement for biosimilars will cost the U.S. billions - STAT

STAT Plus: Inappropriate ‘interchangeability’ requirement for biosimilars will cost the U.S. billions

By VIJAY RAMAKRISHNAN AND EDWIN P. CHING

ADOBE

Requiring biosimilars to earn an "interchangeable biosimilar" label for pharmacy substitution will damage their affordability and access to them in the U.S.

READ MORE